Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)101.91
  • Today's Change-2.99 / -2.85%
  • Shares traded32.99m
  • 1 Year change+79.23%
  • Beta1.2326
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

WuXi AppTec Co Ltd is a China-based company principally engaged in the business of new drug research and development and manufacturing services. The Company conducts its business through six segments. The WuXi Chemistry Segment is primarily engaged in providing new drug research, development and manufacturing services. The WuXi Testing Segment is primarily engaged in providing pharmaceuticals, medical devices, and in vitro diagnostic reagents services. The WuXi Biology Segment is primarily engaged in providing drug discovery and research services. The WuXi ATU Segment is primarily engaged in providing customers with integrated medical product process development, manufacturing and testing services. The WuXi DDSU Segment is primarily engaged in providing customers with integrated new drug research and development services. The Other Segment is primarily engaged in administrative services, sales of raw materials and sales of waste materials.

  • Revenue in CNY (TTM)44.40bn
  • Net income in CNY14.99bn
  • Incorporated2000
  • Employees39.41k
  • Location
    WuXi AppTec Co Ltd228 Fute Zhong RoadWaigaoqiao Free Trade ZoneSHANGHAI 200131ChinaCHN
  • Phone+86 2 150461000
  • Fax+86 2 150463093
  • Websitehttps://www.wuxiapptec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Akeso Inc2.51bn-846.95m85.74bn3.53k--12.97--34.11-1.09-1.093.258.120.21150.77263.95936,947.80-7.07-8.38-8.20-9.8279.26---33.46-33.184.01-536.980.4168---53.0897.39-125.37--34.14--
Sichuan Kelun-Biotech Biophrmctcl Co Ltd1.50bn-722.97m86.28bn1.87k--17.19--57.43-3.65-3.657.5424.350.30674.9313.37925,245.40-14.76---17.11--57.10---48.12--6.32--0.0255--25.48--53.54------
WuXi Biologics (Cayman) Inc20.08bn4.20bn146.29bn12.55k35.723.2021.977.291.121.125.4212.510.34426.363.061,806,232.008.457.9810.579.9542.6542.7124.5425.822.69--0.09430.009.6336.21-1.2827.053.97--
BeOne Medicines AG35.67bn-153.00m294.74bn11.08k--13.71--8.26-0.1999-0.199924.4920.400.75161.477.053,221,068.00-0.3223-22.78-0.4778-30.0785.9983.69-0.4289-72.742.174.500.2209--56.1955.9125.87--40.78--
WuXi AppTec Co Ltd44.40bn14.99bn308.03bn39.41k19.484.11--6.945.235.2315.4924.800.52593.704.821,126,406.0017.9712.3222.3915.6845.0039.1234.1722.922.36--0.098330.00-2.7324.97-1.6338.509.6037.38
Data as of Feb 13 2026. Currency figures normalised to WuXi AppTec Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

17.84%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 2025100.34m3.92%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202573.39m2.87%
Hwabao WP Fund Management Co., Ltd.as of 10 Sep 202457.50m2.25%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 202549.40m1.93%
China Asset Management Co., Ltd.as of 10 Sep 202448.50m1.90%
Harvest Fund Management Co., Ltd.as of 30 Jun 202536.14m1.41%
China Merchants Fund Management Co., Ltd.as of 30 Jun 202525.91m1.01%
China Southern Asset Management Co., Ltd.as of 30 Jun 202523.37m0.91%
GF Fund Management Co., Ltd.as of 30 Jun 202521.98m0.86%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 202520.05m0.78%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.